Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Acquired by Cambridge Trust Co.

Cambridge Trust Co. grew its position in Vera Therapeutics, Inc. (NASDAQ:VERA) by 386.6% in the first quarter, HoldingsChannel reports. The institutional investor owned 48,107 shares of the company’s stock after acquiring an additional 38,220 shares during the period. Cambridge Trust Co.’s holdings in Vera Therapeutics were worth $2,074,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of VERA. Ameritas Investment Partners Inc. lifted its holdings in shares of Vera Therapeutics by 20.8% in the 1st quarter. Ameritas Investment Partners Inc. now owns 4,000 shares of the company’s stock valued at $172,000 after purchasing an additional 688 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Vera Therapeutics in the 4th quarter worth approximately $79,000. Cetera Advisors LLC acquired a new stake in shares of Vera Therapeutics in the 1st quarter worth approximately $235,000. Capstone Investment Advisors LLC acquired a new stake in Vera Therapeutics during the 1st quarter valued at $248,000. Finally, SG Americas Securities LLC acquired a new stake in Vera Therapeutics during the 4th quarter valued at $119,000. 99.21% of the stock is owned by institutional investors and hedge funds.

Vera Therapeutics Stock Down 0.6 %

NASDAQ:VERA traded down $0.23 during mid-day trading on Friday, hitting $37.39. The company had a trading volume of 763,737 shares, compared to its average volume of 536,064. The business has a fifty day simple moving average of $36.45 and a 200-day simple moving average of $38.72. The company has a current ratio of 28.63, a quick ratio of 28.63 and a debt-to-equity ratio of 0.14. Vera Therapeutics, Inc. has a 1 year low of $9.24 and a 1 year high of $50.78.

Vera Therapeutics (NASDAQ:VERA) last announced its earnings results on Thursday, May 9th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.03). As a group, equities analysts expect that Vera Therapeutics, Inc. will post -2.34 EPS for the current year.

Wall Street Analyst Weigh In

VERA has been the topic of a number of analyst reports. Raymond James increased their target price on Vera Therapeutics from $57.00 to $68.00 and gave the company a “strong-buy” rating in a report on Friday, May 10th. JPMorgan Chase & Co. increased their target price on Vera Therapeutics from $60.00 to $65.00 and gave the company an “overweight” rating in a report on Friday, May 31st. Finally, Guggenheim reissued a “buy” rating and set a $56.00 price target on shares of Vera Therapeutics in a research note on Friday, April 5th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Vera Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $42.86.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.